This site is for US healthcare professionals to provide online access to current, accurate, scientific information about our products. It is prepared by Janssen Medical Information and is not intended for promotional purposes, nor for medical advice.

  1. Home
  2. Announcements
  3. Selected Announcement

Neuroscience Conferences

Janssen-sponsored congress materials from select Neuroscience Conferences:

 

Data presented at the 2021 Psych Elevate Annual Meeting

Please refer to the Psych Elevate website directly for oral presentations and posters available for registered attendees at: https://virtual.elevate.psychcongress.com/ or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster title

  • Effect of Paliperidone Palmitate Versus Oral Antipsychotics on Treatment Failure in Black/African American and Young Adult Subpopulations: A Pooled Analysis of Data from the DREaM and PRIDE Studies

 

Data presented at the 2021 American Society of Clinical Psychopharmacology Annual Meeting

Please refer to the ASCP website directly for oral presentations and posters available for registered attendees at: https://ascp.societyconference.com/v2/ or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster titles

  • Long-Term Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study
  • Intranasal Esketamine Effectively Treats Treatment-Resistant Depression in Adults Regardless of Baseline Irritability
  • Evaluation of Treatment Failure in Real-World Management of Patients with Recent-Onset Schizophrenia from the Disease Recovery Evaluation and Modification (DREaM) Study
  • Efficacy and Safety of Esketamine Nasal Spray by Sex in Patients with Treatment-Resistant Depression: Findings from Randomized, Controlled Trials (encore poster)
  • Characteristics of Real-world Commercially Insured Patients Initiated on Esketamine Nasal Spray, or Other Major Depressive Disorder Therapies in the United States (oral presentation)

 

Data presented at the 2021 Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Meeting

Abstracts and select podium presentations & posters from ISPOR conferences can be accessed directly at https://www.ispor.org/heor-resources/presentations-database/search

Abstracts

 

Data presented at the 2021 American Psychiatric Association Annual Meeting

Please refer to the APA website directly for oral presentations and posters available for registered attendees at: https://apa.onlineeventpro.freeman.com/ or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster titles

  • Response to Esketamine Nasal Spray in Patients With Major Depressive Disorder and Acute Suicidal Ideation/Behavior Without Evidence of Early Response
  • Efficacy and Safety of Esketamine Nasal Spray by Sex in Patients With Treatment-Resistant Depression: Findings From Randomized, Controlled Trials
  • Characteristics of United States (US) Veterans With Major Depressive Disorder and Their Current Standard of Care: A Real-Word Data Analysis
  • Universal Acute Care Suicide Screening Among the General Population and Individuals With Major Depressive Disorder in a Large Healthcare System
  • Assessing Expert Consensus Around Progression and Mitigation of Cognitive Decline Following Onset of Schizophrenia Disease: A Delphi Method Study
  • Systematic Review of Schizophrenia Clinical Practice Guidelines: Recommendations on Use of Long-Acting Injectable Antipsychotics in the United States
  • A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on Acute and Maintenance Antipsychotic Treatment
  • Healthcare Resource Utilization and Costs Pre-/Post-Long-Acting Injectable Antipsychotic Use in Commercially Insured Young Adults With Schizophrenia
  • Reductions in Behavioral Healthcare Service Use Among Patients With Schizophrenia Associated With the Covid-19 Pandemic

 

Data presented at the 2021 College of Psychiatric and Neurologic Pharmacists Annual Meeting

Please refer to the CPNP website directly for oral presentations and posters available for registered attendees at: https://cpnp.org/ed/meeting/2021 or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Abstracts

 

Data presented at the 2021 Academy of Managed Care Pharmacy Annual Meeting

Virtual congress materials from the AMCP Annual Meeting can be accessed directly at https://amcpannual2021.pathable.co/

Abstracts

 

Data presented at ACTRIMS 2021

Virtual congress materials from ACTRIMS congress can be accessed directly at https://www.abstractsonline.com/pp8/#!/9245.

Abstracts

 

Data presented at Psych Congress 2020

Virtual congress materials from Psych Congress can be accessed directly at https://www.psychcongress.com/posters.

Posters:

 

Data presented at MSVirtual 2020

Virtual congress materials from MSVirtual congress can be accessed directly at https://library.msvirtual2020.org/virtual-library-search?product_id=7.

Posters

  • Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study – P0071
  • Effect on disability measures and MSFC in patients with relapsing multiple sclerosis from the phase 3 ponesimod versus teriflunomide optimum study – P0204
  • Cardiac Safety of Ponesimod in Relapsing Multiple Sclerosis in the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study -P0194
  • Establishing Meaningful Change Threshold in Multiple Sclerosis related Fatigue on Fatigue Symptoms & Impacts Questionnaire-Relapsing MS (FSIQ-RMS) – P1027
  • Long-term efficacy and safety of ponesimod: Results from randomized phase II core and extension studies in relapsing remitting multiple sclerosis – P0215
  • Treatment Persistency for Patients in a Phase 2 Long-Term Extension Study of Ponesimod – P0177
  • Pharmacokinetic-Pharmacodynamic Models of Lymphocyte Count and Heart Rate Following Ponesimod Dosing in a Phase 2 Study in Multiple Sclerosis Patients – P0224
  • A real-world study characterizing symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis using a novel disease specific scale – P1004
  • Comorbidity and Economic Burdens of Fatigue Among Patients with Relapsing-Remitting Multiple Sclerosis in the United States – P0857
  • Treatment Preferences of Patients with Relapsing Multiple Sclerosis: A Discrete Choice Experiment – P1064
  • Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Model-Based Meta-Analysis for Annual Relapse Rate – P0049
  • Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Longitudinal Model-Based Meta-Analysis for Confirmed Disability Accumulation – P0048
  • Quality of life and economic burden of fatigue in people with multiple sclerosis: a systematic literature review – P1048